Hotelbuchung
Hotel Registration
Grußwort
Welcome address
Beteiligte Gesellschaften
Societies involved
DOG Information
DOG Information
Eröffnung des Kongresses
Opening Ceremony
Preise
Awards
Ablauf der Tagung 2003
General overview of congress
Lageplan der Räumlichkeiten
Map of Congress Center
Wissenschaftliche Themen
Scientific topics
Symposien
Symposia
Wissenschaftliches Programm
Scientific program
Posterpräsentationen
Poster Presentation
Kurse
Courses
Begleitende Veranstaltungen
Accompanying program
Arbeitssitzungen
Working sessions
Rahmenprogramm
Social program
Allgemeine Informationen
General Information
Autorenindex
Index of Authors
Industrieaussteller
Commercial exhibitors
Sponsoren
Sponsors
Impressum
DOG Homepage
Abstract
Abstract
TSH-Receptor-Antibodies (TSHR-AB) Help to Predict Severity and Outcome of Graves Ophthalmopathy (GO)
Eckstein A.1, Plicht M.1, Morgenthaler N.4, Steuhl K. P.1, Renzing-Köhler K.3, Quadbeck B.2, Mann K.2, Esser J.1
1Department of Ophthalmology, 2Department of Medicine, Division of Endocrinology, 3Institute for Medical Informatics, Biometry and Epidemiology, University Essen; 4BRAHMS AG, Research, Biotechnology Centre Hennigsdorf/Berlin, Germany
Purpose: There are no useful biomarkers known to assess the prognosis of the GO, which makes the management of GO very difficult. The association between TSHR-AB and GO is still a mater of debate. The aim of this study was to evaluate the value of TSHR-AB for the prognosis of GO by the retrospective analysis of prospectively collected follow up data of GO patients.
Method: 67 patients with GO have been followed for two years. Patients were divided into two groups (according to the course of the clinical activity score (CAS) and the severity the disease: modified NOSPECS score). Severe GO (n=30): CAS >8, NOSPECS >7 at first visit, CAS 4-7, NOSPECS 3-6 at first visit with increasing or unchanging values, CAS <4, NOSPECS <3 at first visit and increasing values. Mild to moderate GO(n=37): CAS 4-7, NOSPECS 3-6 at first visit with decreasing values or CAS <4, NOSPECS <3 at first visit with maintaining or decreasing values. TSHR-AB (TBII, TRAKhuman, BRAHMS, Germany) were measured w